New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

242

Enrollment

OTHER

Sponsor class

Conditions

BPH (Benign Prostatic Hyperplasia)
Lower Urinary Track Symptoms

Interventions

DRUG: raloxifene
DRUG: Finasteride

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]